Carregant...
The next forum for unraveling FDA off-label marketing rules: State and federal legislatures
In a Guest Editorial, Aaron S. Kesselheim and Michael S. Sinha show how federal and state legislation to allow promotion of drugs for non-approved uses threatens to undermine the FDA's public health mission.
Guardat en:
| Publicat a: | PLoS Med |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Public Library of Science
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5940176/ https://ncbi.nlm.nih.gov/pubmed/29738523 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002564 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|